AbCellera Biologics Inc.
HealthcareNASDAQ:ABCL · NASDAQ Global Select
-$0.03 today
Vol 2.94M · Avg 6.25M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-15.1%
avg -2.5%
ROIC
-13.8%
avg -5.0%
ROA
-10.8%
avg -0.9%
Analysis
ROA is currently the strongest return metric at -10.8% versus its period average of -0.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Carl Hansen | Chief Executive Officer, President & Chairperson | $931,152.00 | — | 51 | $13.10M | 4.29% |
Andrew Booth | Chief Financial Officer | $726,811.00 | — | 52 | $195,600.00 | 0.06% |
Tryn T. Stimart | Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer | $709,275.00 | — | 56 | $4.65M | 1.52% |
Veronique Lecault | Chief Technology Officer & Director | $681,646.00 | — | 41 | $5.20M | 1.70% |
Tiffany Chiu | Vice President of Communications | — | — | — | — | — |
Caitlin Webster CIPD | Director of Talent Development | — | — | — | — | — |
Marcie Thiessen | Senior Director of Finance & Accounting | — | — | — | — | — |
Adam Clarke | Senior Vice President of Discovery | — | — | — | — | — |
Andrew Knowles | Vice President of Operations | — | — | — | $195,600.00 | 0.06% |
Martin Hogan | Senior Director of Strategic Finance & IR | — | — | — | — | — |
Murray McCutcheon | Senior Vice President of Partnering | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$1.13M
Sells
0
$0.00
Net Sentiment
+$1.13M
Net buying
Most Active
Montalbano John S.
2 transactions
Analysis
Insiders reported 5 buys worth $1.13M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $1.13M. Montalbano John S. was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +247.1% | -15.7% (8yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +247.1% over three years. Forward estimates point to Revenue at -15.7% (8yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Spyre Therapeutics, Inc.
NASDAQ:SYRE
$4.88B
Vera Therapeutics, Inc.
NASDAQ:VERA
$2.46B
Pharvaris N.V.
NASDAQ:PHVS
$2.15B
Celldex Therapeutics, Inc.
NASDAQ:CLDX
$2.08B
Immunome, Inc.
NASDAQ:IMNM
$1.76B
Nuvation Bio Inc.
NYSE:NUVB
$1.71B
Sionna Therapeutics, Inc.
NASDAQ:SION
$1.62B
Biohaven Ltd.
NYSE:BHVN
$1.19B
Xeris Biopharma Holdings, Inc.
NASDAQ:XERS
$1.17B
Janux Therapeutics, Inc.
NASDAQ:JANX
$826.95M
Who manages ABCL?
AbCellera Biologics Inc. (ABCL) lists 11 active executives. The top listed executive is Tiffany Chiu, Vice President of Communications.
Are ABCL insiders buying or selling?
Recent insider activity shows net selling of $124.71M.
Explore More
Continue the stock analysis
Jump to another research area for this company.